Baker Bros. Advisors Adjusts BeiGene Stake

TL;DR

Baker Bros. Advisors updated their BeiGene stake filing. Keep an eye on this.

AI Summary

Baker Bros. Advisors LP, through its affiliates FBB3 LLC and Baker Bros. Advisors (GP) LLC, has amended its Schedule 13D filing concerning BeiGene, Ltd. as of December 10, 2024. The filing indicates a significant stake in the company, with the group members collectively holding a substantial number of ordinary shares. This amendment likely reflects changes in their holdings or strategic intentions regarding BeiGene.

Why It Matters

This filing provides insight into the investment strategy of a major biotech-focused investment firm regarding a significant player in the oncology space, potentially influencing market perception and stock movement.

Risk Assessment

Risk Level: medium — Changes in holdings by significant institutional investors can signal shifts in market sentiment or strategic corporate actions, posing a medium risk to investors.

Key Players & Entities

• Baker Bros. Advisors LP (company) — Filer of the Schedule 13D/A
• BeiGene, Ltd. (company) — Subject company
• FBB3 LLC (company) — Affiliate of Baker Bros. Advisors LP
• Baker Bros. Advisors (GP) LLC (company) — Affiliate of Baker Bros. Advisors LP
• Felix J. Baker (person) — Group member
• Julian C. Baker (person) — Group member

FAQ

Key Financial Figures

• $0.0001 — of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securiti
• $12.23 — Share Options with an exercise price of $12.23 per Ordinary Share which were granted o
• $208.000 — e transactions at a prices ranging from $208.000 to $208.185. The Reporting Persons unde
• $208.185 — ns at a prices ranging from $208.000 to $208.185. The Reporting Persons undertake to pro

Filing Documents

• tm2430688d1_sc13da.htm (SC 13D/A) — 110KB
• 0001104659-24-127397.txt ( ) — 112KB

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer.

of this Schedule 13D is hereby supplemented and amended, as

Item 5 of this Schedule 13D is hereby supplemented and amended, as the case may be, as follows: (a) and (b) Items 7 through 11 and 13 of each of the cover pages of this Amendment No. 11 are incorporated herein by reference. Set forth below is the aggregate number of Ordinary Shares of BeiGene, Ltd. (the “Issuer”) directly held by the Funds, 123,914,440 of which are directly held by the Funds through American Depositary Shares (“ADS”) , along with the percentage of the Issuer’s outstanding Ordinary Shares such holdings represent. Each ADS represents 13 Ordinary Shares of the Issuer. The information set forth below is based on 1,386,034,320 Ordinary Shares outstanding at November 1, 2024 as reported in the Issuer’s Form 10-Q filed with Securities and Exchange Commission (“SEC”) on November 12, 2024. Such percentage figures are calculated in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended. Name Number of Ordinary Shares we own or have the right to acquire within 60 days Percent of Class Outstanding 667, L.P. 10,289,430 0.7 % Baker Brothers Life Sciences, L.P. 113,625,056 8.3 % Total 123,914,486 9.0 % Michael Goller and Ranjeev Krishana, full-time employees of the Adviser, have served on the Board since April 21, 2015 and October 7, 2014, respectively. Michael Goller and Ranjeev Krishana currently serve on the Board as representatives of the Funds. Michael Goller and Ranjeev Krishana each hold 406,536 options to purchase Ordinary Shares (“Share Options”) received in connection with their service on the Board which are exercisable within 60 days from the date of this Amendment No. 11. Michael Goller and Ranjeev Krishana each hold 46,696 Ordinary Shares which were received upon the vesting of restricted stock units (each, an “RSU”) in connection with their service on the Board. Michael Goller and Ranjeev Krishana each hold 16,341 RSUs and 34,151 S

View Full Filing

View this SC 13D/A filing on SEC EDGAR